Member Info for Aether

HSD something's going on.

There's a big order at L2.

I think you're right people are preparng for news.

The ITN programme will be interesting. When's it being published?

Green bin it.

Don't feed it.

Over on ADVFN, in response to a claim that "Something's afoot", someone stated:

"Yes almost 4 million shares on the bid in 4 lots above 17p on level 2. The potential purchaser is there to be taken out so must be really prepared to buy 3.8 million shares.

All very curious but I’m sure everything will become clear in time. Of course Polygon need just under 2% to get to 29.99% (the max they can go to without making a bid) so perhaps these bids are from them"

If this is true, someone is keen to buy.

Why?

Those are large buy orders.

You can guage it by the subsequent share price movement.

ShareMedical on Twitter claims:

"So Good morning. The buyer wants close to 2% of the company before news. It's all showing now on Level2 !"

Is this true?

An awareness of the health challanges presented by COVID and the political will to do something about it is still there.

The sums available will be huge if the relevant legislation can pass Congress.

However, Congress is now controlled by the Republicans with a majority of 8 representatives.

https://www.cbsnews.com/news/white-house-covid-19-ukraine-aid-congress/

Washington — The White House on Tuesday asked Congress to provide another $10 billion to combat COVID-19 and other infectious diseases amid an emergence of new subvariants and expected winter surge in infections, as well as an additional $37.7 billion in support for Ukraine to defend itself from Russia's ongoing aggression.

...

"Staying ahead of COVID-19. Supporting Ukraine's fight to defend its sovereignty. Helping Americans who have borne the brunt of natural disasters," she said. "The American people rightly expect their leaders to come together and deliver on these priorities."

According to a breakdown of the request provided by the White House, the $10 billion for funding to fight COVID-19 and other diseases includes $2.5 billion to ensure continued access to vaccines and therapeutics; $5 billion to support the development of next-generation vaccines and therapeutics; and $750 million to support research and treatment for long COVID, the term for cases in which symptoms linger for months or even years. The Biden administration is seeking $750 million of the $10 billion requested to restore smallpox vaccines used for the monkeypox response, and to start procuring and distributing treatment for hepatitis C and pre-exposure prophylaxis to help prevent HIV.

"While COVID-19 is no longer the disruptive force it was when the president took office, we face the emergence of new subvariants in the United States and around the world that have the potential to cause a surge of infections, hospitalizations, and deaths, particularly as we head into the winter months — a time when viruses like COVID-19 spread more quickly," Young wrote.

The White House has attempted on multiple occasions to get more money from Congress to bolster the resources it says are needed to address the pandemic, and is renewing its efforts during the lame-duck session between the midterm elections and the seating of a new Congress.

"Failure to provide more funding would lead to needless infections and deaths across the nation and around the world," Young told Pelosi.

Green bin it.

Don't feed it.

Burstead also supports Italy.

Agreed, HSD and sativa.

If there's no positive news about a PT or JV, the share price will gradually ebb to reflect the cash that remains.

The next 2-3 months are make or break for shareholders.

The recent job adverts for an unamed organization in Southampton is important.

Are they for Synairgen or just an organization related to the university?

Also, was the recent Quality Control job withdrawn because it had been filled or no longer needed?

Thank you, Mani.

So, the jobs we got excited about the other day MAY be for this trial and for Southampton University not Synairgen.

:)

COULD this be for one of the clinical trials run by Southampton University, for example, Universal, rather than for Synairgen?

Prof Tom Wilkinson at Southampton is involved with the latter trial and has been involved with Synairgen.

Why wouldn't an organization want to reveal their name at this stage in the recruitment process?

More sleuthing is needed on this.

Southampton University recently issued a tweet about it's pharmaceutical related work.

Could this position be related to that rather than Synairgen?

Good work, Mani.

What's your take on this?

Can someone whose had previous connection with Synairgen find out? I've sent to two questions to Brooke previously but no response.

Thanks!